Home/Filings/4/0001012975-25-000621
4//SEC Filing

Southpoint GP, LP 4

Accession 0001012975-25-000621

CIK 0001211583other

Filed

Oct 8, 8:00 PM ET

Accepted

Oct 9, 5:31 PM ET

Size

16.7 KB

Accession

0001012975-25-000621

Insider Transaction Report

Form 4
Period: 2025-10-07
Transactions
  • Sale

    Common Stock

    2025-10-09$9.35/sh20,609$192,6144,010,100 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-07$9.59/sh26,900$257,8934,050,314 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-08$9.47/sh19,605$185,7224,030,709 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2025-10-07$9.59/sh26,900$257,8934,050,314 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-08$9.47/sh19,605$185,7224,030,709 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-09$9.35/sh20,609$192,6144,010,100 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2025-10-07$9.59/sh26,900$257,8934,050,314 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-09$9.35/sh20,609$192,6144,010,100 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-08$9.47/sh19,605$185,7224,030,709 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2025-10-07$9.59/sh26,900$257,8934,050,314 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-09$9.35/sh20,609$192,6144,010,100 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-08$9.47/sh19,605$185,7224,030,709 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2025-10-07$9.59/sh26,900$257,8934,050,314 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-08$9.47/sh19,605$185,7224,030,709 total(indirect: See Footnote)
  • Sale

    Common Stock

    2025-10-09$9.35/sh20,609$192,6144,010,100 total(indirect: See Footnote)
Footnotes (4)
  • [F1]The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.
  • [F2]The transaction was executed in multiple trades at prices ranging from $9.47 to $9.70. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
  • [F3]The transaction was executed in multiple trades at prices ranging from $9.31 to $9.61. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
  • [F4]The transaction was executed in multiple trades at prices ranging from $9.30 to $9.42. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

Issuer

FENNEC PHARMACEUTICALS INC.

CIK 0001211583

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001378376

Filing Metadata

Form type
4
Filed
Oct 8, 8:00 PM ET
Accepted
Oct 9, 5:31 PM ET
Size
16.7 KB